(COLL) Collegium Pharmaceutical, Inc. Business Model Canvas Research

Pharmacy benefit managers shape Collegium Pharmaceutical, Inc.'s access to patients by setting formulary status, copays, and prior-authorization rules. In U.S. branded drugs, that market-access gate can make or break volume, so Collegium works with PBMs to widen coverage for prescribed therapies and reduce friction at the pharmacy counter.

• Controls formulary access and utilization
• Influences patient copays and coverage
• Directly drives branded-drug volume

Specialty pharmacies and hub vendors handle prescription routing, prior authorizations, refill checks, and patient onboarding for Collegium Pharmaceutical, Inc., which helps turn prescriptions into fills and keep patients on therapy. For a pain-and-CNS portfolio sold through controlled channels, this support matters because faster approval and refill coordination can lift adherence and reduce abandonment.

• Speed prior authorization
• Coordinate refills
• Support onboarding
• Improve fill conversion
• Help adherence

Collegium Pharmaceutical, Inc. uses market access execution to win formulary placement, rebates, and coverage terms, which cuts friction for prescribers and patients in opioid and branded pain markets. In 2025, that access work remained key for products like Xtampza ER and Belbuca, where payer coverage can shape net sales and patient starts.

• Formulary positioning
• Rebates and coverage terms
• Reduces patient barriers

Collegium Pharmaceutical, Inc. keeps tight oversight on outside manufacturing, quality, and supply planning for controlled-dosage products, where batch traceability and distribution discipline are critical. In 2025, the company generated about $590 million in net revenue, so supply reliability directly supports cash flow and product availability.

• External plant oversight
• Batch control and QA checks
• Supply continuity focus

Collegium Pharmaceutical, Inc.'s commercial organization is a core key resource: a specialized sales and market access team links physicians, payers, and pharmacies to drive access for its pain portfolio. In FY2024, Collegium Pharmaceutical, Inc. generated about $742.7 million in net product revenues, showing how commercial execution directly supports scale and reimbursement.

• Specialized sales and market access coverage
• Connects physicians, payers, pharmacies
• Drives revenue and reimbursement execution

Collegium Pharmaceutical, Inc. keeps its corporate headquarters in Stoughton, Massachusetts, and in 2025 this single U.S. hub anchors leadership, planning, finance, and oversight. That centralized base supports a lean operating model and faster decision-making.

• 1 headquarters in Stoughton
• Centralizes leadership and finance
• Supports oversight and planning

Collegium Pharmaceutical, Inc. stays tightly focused on pain management, which lets it build deeper prescriber ties and run more targeted sales calls than a broad-pipeline peer. In 2024, the Company generated roughly $700 million in net product revenue, showing that this niche focus can support scale while sharpening category expertise.

• Focuses on pain, not many therapy areas
• Supports deeper prescriber relationships
• Enables sharper commercial execution
• Builds pain-category expertise

Collegium Pharmaceutical, Inc. uses patient support, reimbursement help, and pharmacy coordination to speed therapy starts and cut friction for branded prescriptions. Industry data show nearly 1 in 3 prescriptions can be abandoned when access is hard, so these services matter for adherence and persistence.

• Speed therapy initiation
• Ease reimbursement delays
• Support adherence and persistence

Collegium Pharmaceutical, Inc.’s medical information team must give fast, accurate answers on safety, dosing, and product use for its four-product pain portfolio, including clinicians and pharmacies. That one-to-one support helps keep prescribing aligned with label guidance and strengthens trust and compliance.

• Answers safety and dosing questions
• Supports clinicians and pharmacies
• Builds trust and compliance

Collegium Pharmaceutical, Inc. depends on tight pharmacy coordination because retail and specialty pharmacies must keep prior authorizations and refill fixes moving fast; even small delays can slow fills and hurt access. In 2024, Collegium Pharmaceutical reported net product revenues of about $600 million, so smoother pharmacy execution matters directly to cash flow.

• Coordinates across retail and specialty pharmacies
• Fixes prior auth and refill issues fast
• Improves fill rates and revenue conversion

Collegium Pharmaceutical, Inc. uses field sales and medical liaison teams for direct HCP engagement, so prescribers get product education at the office level. This is a key pharma promotion channel because its portfolio has recently generated over $700 million in annual net product revenue, making in-person reach a core demand driver.

• Direct HCP education and office access
• Supports prescription awareness and adoption
• Core channel in pharma promotion

Digital access and hub services are a key channel for Collegium Pharmaceutical, Inc.: they speed enrollment, benefits checks, and reimbursement so patients can start therapy faster. In 2025, these services supported access across Collegium Pharmaceutical, Inc.'s 3 branded pain products and helped coordinate patient support before first fill.

• Faster enrollment
• Benefits verification
• Reimbursement support
• Less first-fill delay

Hospitals and health systems matter because institutional prescribers and discharge teams shape first pain starts; in the U.S., about 6,100 hospitals and 208,000 employed physicians can steer that choice. Formulary access inside these systems can lift or block use, so Collegium Pharmaceutical, Inc.'s hospital ties help expand broader utilization.

• Formulary access drives starts
• Discharge workflows influence therapy
• System ties support repeat use

Payers and pharmacy benefit managers are Collegium Pharmaceutical, Inc.'s main access gatekeepers, not end users. They decide coverage, tiering, and prior authorization, and PBMs manage pharmacy benefits for roughly 270 million Americans, so their rulings can swing demand fast.

• Control coverage and formulary access
• Shape tiering and utilization rules
• Directly affect prescription volume

Rebates, chargebacks, and returns cut Collegium Pharmaceutical, Inc. net revenue after sale, and in branded pharmaceuticals these gross-to-net deductions often run 15%-30% of gross sales. Access deals can win formulary coverage, but they do it by trading list price for lower realized revenue.

• Rebates lower payer net price.
• Chargebacks hit wholesaler sales.
• Returns add another deduction.

Collegium Pharmaceutical, Inc.’s G&A and compliance spend covers finance, legal, HR, IT, and pharmacovigilance, and it stays high because a controlled-substance model needs tight monitoring and steady regulatory support. Litigation and FDA risk also keep this line item sticky, so it acts like a fixed cost base rather than a one-time expense.

• Finance, legal, HR, IT, pharmacovigilance
• Ongoing regulatory and litigation costs
• Required for controlled-substance operations

Collegium Pharmaceutical, Inc. books revenue net of rebates, discounts, chargebacks, returns, and allowances, which is standard in pharma. In its latest reported year, net product sales were about $737 million, so gross-to-net management is a core driver of revenue quality and margin.

• Revenue is net of payer deductions.
• Gross-to-net controls net sales.
• Pharma reporting follows this method.

Collegium Pharmaceutical, Inc. monetizes U.S. prescription channel sales mainly through wholesalers and pharmacies, with branded domestic drugs driving cash conversion. This channel is the core revenue engine, because cash is realized when products move through the U.S. dispensing network.

• Wholesalers and pharmacies drive U.S. cash inflow
• Branded U.S. sales are the main revenue base
• Dispensing volume directly shapes realized revenue